At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 25 enrolled
Drug / intervention
Metformin +1 moredrug
Likely dose
Metformin 500 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Metformin to Prevent the Metabolic Complications of Olanzapine
In Brief
A Phase 4 clinical trial evaluating Metformin and Placebo for Metabolic Complications. Completed, enrolled 25 participants across 1 site.
Detailed Summary
We hypothesize that metformin co-administered with olanzapine will be well tolerated and associated with significantly less insulin resistance, weight gain and dyslipidemia as compared to olanzapine plus placebo.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetabolic Complications
CountriesUnited States
CollaboratorsEli Lilly and Company
Timeline
Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartAug 2007
First PostedMay 2008
Primary CompletionAug 2011
TodayJul 2026
First PostedMay 22, 2008
Enrollment StartAug 1, 2007
Primary CompletionAug 1, 2011
TodayJul 2, 2026
Enrollment to primary: 4 yearsPosted 18.1 years ago
Interventions
Metformindrug
Drug: Metformin 500 mg po daily titrated up to but no greater than 2000 mg based upon fasting blood glucose during study visits over six months.
Placebodrug
Drug: Placebo. Subjects will remain on placebo for 6 months.